Articles tagged with Crohn Disease
The American Gastroenterological Association (AGA) recommends early introduction of biologics for patients with moderate-to-severe luminal and fistulizing Crohn's disease. Biologics are the most effective treatment option, which should be used early rather than delaying their use until other treatments fail.
Researchers found selective patterns of antibody reactivity to microbiota flagellins among Crohn's disease patients, with augmented serum IgG antibodies to Lachnospiraceae flagellins. These findings suggest a potential target for prognosis and personalized therapies in Crohn's disease.
Researchers found that T cells in the small intestine have evolved a molecular sensing mechanism to protect themselves from toxic bile acids. This mechanism can be manipulated with small drug-like molecules, reducing inflammation and improving symptoms.
A study led by McMaster University identified adherent-invasive E-coli (AIEC) as a strong potential trigger for Crohn's disease. AIEC bacteria are often found in the intestines of people with Crohn's, and research suggests that they can cause the condition by allowing them to freely colonize the gut lining.
Researchers at Mount Sinai Hospital have identified genetic and cellular mechanisms underlying Crohn's disease, providing new insights for tailored treatments. By blocking the gp130 protein, they found that some patients may benefit from alternative therapies, complementing standard anti-TNF treatments.
A study published in Science reveals that a fungus found in foods like cheese and processed meats can infect sites of intestinal damage in mice and people with Crohn's disease, preventing healing. Treating infected mice with antifungal medication allows wounds to heal.
Researchers found a type of yeast called Debaryomyces hansenii elevated in areas of unhealed wounds in Crohn's disease patients. The study suggests targeting this infection may be a viable approach to treat or prevent the disease, and further studies are needed.
A new anti-inflammatory nanotherapy has shown promising results in reducing intestinal inflammation and shrinking lesions in a rodent model of severe Crohn's disease. The approach could potentially replace biologic antibody therapies with fewer side effects.
A new study reveals a 'weak point' in a type of gut bacteria that causes intestinal inflammation in patients with Crohn's disease. The researchers found that interfering with the bacteria's process relieved gut inflammation in a mouse model of Crohn's disease.
A potential preventative treatment for Crohn's disease has been demonstrated using a triple-punch treatment to remove T memory cells and increase T regulatory cells, preventing colitis in both mouse models and patient cells. This treatment approach may offer a new immunotherapy to prevent or ameliorate inflammatory bowel disease.
A study by University of Cambridge researchers found specific cell functions reactivated in the gut of children with Crohn's Disease. The research provides insight into fundamental molecular mechanisms of human gut development and may lead to childhood-specific treatments.
Researchers identified Clostridium innocuum as the microbial invader triggering 'creeping fat' in Crohn's patients. The initial response is protective but can contribute to severe intestinal scarring and fibrosis.
Researchers have developed a wearable device that monitors sweat for key biomarkers associated with inflammatory bowel disease (IBD), which could indicate flare-ups. The device has the potential to empower patients to be actively engaged in monitoring their disease and managing it.
A large study found that antibiotic use, especially broad-spectrum antibiotics, is associated with an increased risk of new-onset inflammatory bowel disease (IBD) and its subtypes. The study suggests that perturbing the gut microbiome may impact the risk of gastrointestinal disease.
Research links inflammatory bowel disease (IBD) to a doubled risk of developing dementia, with diagnoses occurring 7 years earlier. The study suggests that an imbalance in gut bacteria and chronic inflammation may contribute to cognitive decline.
Researchers at the University of Houston have identified three different stem cell types in Crohn's biopsies, with two variants contributing to inflammation and fibrosis. The team is developing new drug therapies to selectively destroy these rogue cells and create new treatments for pediatric and adult Crohn's disease.
A new study suggests that steroid-sparing therapies can reduce the risk of developing perianal fistulas in children and young adults with Crohn's disease. These treatments have been found to be nearly 60% less effective in developing fistulas, and if they do occur, those treated with such therapies are 55% less likely to undergo surgery.
A new special issue of Clinical Gastroenterology and Hepatology highlights major advances in IBD treatment. The issue provides comprehensive updates on algorithmic treatments to reduce morbidity and emphasizes the importance of treating beyond symptom relief.
Researchers at the Australian Centre for Digestive Diseases have successfully treated Crohn's disease in patients, achieving prolonged remission of 3-23 years. The treatment uses a combination of specific antibiotics and Faecal Microbiota Transfer (FMT) to repopulate the gut with healthy bacteria.
Researchers discovered that microscopic alterations in stem cell niche can predict Crohn's disease recurrence. A therapeutic approach using dichloracetate (DCA) restored intestinal stem cell functionality and maintained the intestinal barrier.
Women with IBD had higher rates of Caesarean section and intrauterine growth retardation compared to those without IBD. Those with mild Crohn's disease did as well during pregnancy as women without IBD, but those with more severe disease experienced increased miscarriage and low birth weight.
Researchers identified predictive models for Crohn's disease, including a serum biomarker model with 76% accuracy, and explored the link between metal exposure in early life and IBD risk. Achieving deep remission early on was also associated with a significant decrease in long-term complications.
Breakthrough research presents five major advances in inflammatory bowel disease (IBD) treatment, including a new drug pipeline, a diet that improves symptoms, and a fecal microbiota transplantation approach. These studies offer hope for patients with Crohn's disease and ulcerative colitis.
Researchers at Case Western Reserve University have discovered a crucial connection between interleukin-1α and gut microbiome function in a mouse model of Crohn's disease. Blocking this protein reduces intestinal inflammation severity, with effects comparable to steroids, which are the current gold standard treatment.
A new study suggests that Tr1 cells, a type of T cell, can produce a chemical signal to repair the gut barrier and promote mucus production. The researchers found that these cells are capable of reducing inflammation and healing tissue in children with IBD.
A new study found that IBD cases are three times higher than previously reported, with ulcerative colitis and Crohn's Disease prevalence increasing by 55% and 83%, respectively. The study also predicts a rise in IBD prevalence by almost a quarter from 2017 to 2025.
A UK-wide collaboration has identified a genetic variant carried by 40% of the population that explains why some patients develop antibodies against anti-TNF drugs and lose response. This discovery could lead to individualized treatment strategies for patients with Crohn's disease.
A Rutgers-led study uses artificial intelligence to examine genetic signatures of Crohn's disease, revealing previously undiscovered genes linked to the illness. The AI method accurately predicted whether thousands of people had the disease, holding promise for improved diagnosis and treatment.
Researchers at The Mount Sinai Hospital have identified a unique cell signature associated with drug resistance in Crohn's disease patients. This discovery may enable the development of personalized treatment plans and improved patient outcomes.
A new pathway has been identified as a potential treatment target for Crohn's disease, a form of inflammatory bowel disease that affects millions in the US. The study suggests that blocking a specific protein receptor may ameliorate inflammation and fibrosis in CD patients.
Researchers found that Edinburgh has the highest rate of inflammatory bowel disease globally, with one in 98 people expected to be affected by 2028. The study highlights the need for more resources to provide patients with research, treatment, and care.
A plant-based diet followed by a man with Crohn's disease led to complete mucosal healing and remission after removing animal products from his diet. The study supports the idea that high-fiber, plant-based diets may benefit patients with Crohn's disease.
Scientists have made a breakthrough in understanding how macrophage cells respond to certain bacteria, potentially leading to new treatments for Crohn's Disease. The study found that different types of macrophages exhibit distinct molecular mechanisms when switching off their pro-inflammatory behavior.
A study found that infliximab, a biologic therapy, did not result in lower rates of hospitalizations or intestinal surgeries among patients with inflammatory bowel diseases (IBD) in Ontario. Despite improving symptoms for individual patients, the treatment's impact on quality of life and workplace productivity remains uncertain.
A new $1.8 million grant will aid in developing personalized treatments for Crohn's disease through the use of a gut-on-a-chip system, which mimics human gut structure and function. The goal is to uncover triggers and develop more effective therapies, ultimately improving health outcomes.
Researchers at the University of Cambridge have developed a new test that can reliably predict the future course of inflammatory bowel disease in individuals. The accuracy of the test is comparable to similar biomarkers used in cancer, with an accuracy rate of 90-100% in correctly identifying patients who do not require multiple treatm...
Researchers developed a capsule-shaped photoacoustic imaging endoscope to examine intestinal changes in Crohn's disease. The device can differentiate between inflammatory and fibrotic strictures, allowing for more targeted treatment and potentially reducing adverse effects. This technology could also provide real-time diagnostic inform...
A £1.8m funding boost will help researchers at the University of Edinburgh improve diagnosis and treatment outcomes for Crohn's disease, a condition affecting 120,000 people in the UK. The study aims to develop a non-invasive test using blood or stool to determine if the inflamed bowel wall has healed after treatment.
A study published in Alimentary Pharmacology & Therapeutics found that older patients with Crohn's disease can be safely treated with combined immunosuppression. The research showed that remission rates were similar between older and younger patients, and there was no increase in side effects in older patients.
Researchers discover Malassezia yeasts in gut of patients with Crohn's disease, exacerbating intestinal inflammation. Genetic variation associated with immune response to fungi links to disease progression.
Researchers at NIHR Guy's and St Thomas' Biomedical Research Centre develop a treatment involving patients' modified cells, restoring healthy levels of integrin α4β7, effective in treating Crohn's disease. The proposed Tribute Trial will test the treatment's safety and effectiveness.
Studies highlight the importance of treating IBD as a whole person, including reproductive and mental health aspects. Patient-provider communication is key to improving health outcomes and addressing emotional exhaustion associated with IBD.
Studies presented at the Crohn's & Colitis Congress highlight the need for improved diagnosis in IBD patients, which can lead to delayed treatment and increased complications. New biomarkers, such as a blood-based prognostic biomarker, are being developed to predict disease course and personalize therapy.
Studies presented at the Crohn's & Colitis Congress highlight advancements in treatments for patients with inflammatory bowel disease (IBD), including JAK inhibitors and biologics targeting immune cell trafficking. These therapies show promise for effective and safe oral therapeutic options for moderate to severe ulcerative colitis.
Research on gut metagenome of patients with Crohn's disease shows a decrease in beneficial microbes and increased abundance of pathogenic Escherichia coli. The analysis identifies diverse strains of E. coli that can coexist in the human gut, influencing treatment efficacy.
Researchers found that malnutrition in children with Crohn's disease significantly increases the risk of surgical complications and poor outcomes. Children with moderate or severe malnutrition have a higher rate of complications, reoperations, and longer hospital stays compared to non-malnourished patients.
A randomized, placebo-controlled study has shown that cannabis oil can produce clinical remission in up to 65% of individuals with moderately severe Crohn's disease after 8 weeks of treatment. However, the improvement does not appear to result from a dampening down of the underlying inflammatory process.
Researchers pinpointed microRNA-31 as a predictive indicator of clinical outcome and functional relevance in driving the disease. The study uses an artificial gut to culture human biopsy samples and track molecular abundance, offering a personalized testing platform for therapeutic agents.
Researchers found that low colonic miR-31 expression is associated with worse disease outcomes in adults and future development of strictures in children. This discovery has the potential to improve clinical trial designs and develop more personalized therapeutic strategies for Crohn's disease patients.
A UH biologist is using a new grant to study how defects in cellular cross-talk lead to Crohn's disease. By examining stem cells isolated from patients, she hopes to find new targets for drug development and reduce inflammation in the gastrointestinal tract.
Researchers have identified 50 stool proteins that are consistently elevated in patients with inflammatory bowel disease. These biomarkers could help diagnose the condition earlier and more accurately, allowing for quicker treatment. The findings also suggest a potential self-care kit for monitoring the disease.
Researchers discovered tiny DNA fragments, mtDNA, in patients' blood samples that are associated with disease flare-ups. These molecules can trigger an inflammatory response and damage to healthy tissues, causing symptoms of bowel diseases like Crohn's and ulcerative colitis.
Researchers have identified 35 regulatory regions that can distinguish between ulcerous colitis, Crohn's disease, and control subjects with high accuracy. This breakthrough may open new avenues for improved diagnostic methods.
The Critical Path Institute has received a $10 million grant from the Leona M. and Harry B. Helmsley Charitable Trust to identify unmet needs for biomarker development in Crohn's disease. The pre-consortium will focus on laying the groundwork for future regulatory endorsement and accelerate the development of new treatments.
A recent review and analysis of published studies found no consistent association between NSAIDs or acetaminophen use and exacerbation of Crohn's disease. However, a low-bias study showed a link between NSAID use and worsening of Crohn's disease symptoms.
Researchers found that sucralose, a key ingredient in Splenda, promotes gut inflammation in mice with Crohn's-like disease, but has no effect on healthy mice. The study suggests that individuals with pro-inflammatory predispositions may be more susceptible to exacerbation of symptoms.
Researchers at the University of Central Florida have discovered a link between Mycobacterium avium subspecies paratuberculosis (MAP) and rheumatoid arthritis. The bacteria, commonly found in milk and beef, can trigger autoimmune responses in genetically predisposed individuals.
Studies show that home infusions can decrease infusion burden for selected patients and are cost-effective. Telemedicine may also improve outcomes but increases healthcare utilization. Urgent care access and patient education also lead to improved clinical outcomes and satisfaction.
Research presented at the Crohn's & Colitis Congress provides guidance for physicians to enhance IBD patient care. Studies show that better management of anemia improves overall outcomes, while IBD patients need better understanding of CRC screening intervals.
Researchers have made breakthroughs in IBD treatment with the approval of a new antibiotic and the use of Janus kinase inhibitors. These advancements aim to improve outcomes for patients who currently lack effective treatment options.